Eli Lilly announced it will file for approval of its next-generation obesity drug, retatrutide, in Q1 2027, later than previously stated. This follows successful late-stage trials showing significant weight loss in adults with obesity, Type 2 diabetes, and cardiovascular disease.
Danish pharmaceutical giant Novo Nordisk is suing US-based Eli Lilly in a New Jersey court for "false and misleading" advertisements. Novo Nordisk alleges Eli Lilly used "outdated studies" to compare GLP-1 agonist drugs like Wegovy and Ozempic to Mounjaro and Zepbound, causing confusion.
Novo Nordisk is suing Eli Lilly, alleging "false and misleading" advertisements for its weight-loss and anti-diabetes treatments, Zepbound and Mounjaro. Novo Nordisk claims Lilly used outdated studies comparing its highest doses against lower doses of Novo Nordisk's drugs, creating a deceptive impression of superiority. Eli Lilly defends its ads, citing the Surmount-5 trial as the only direct comparison.
Novo Nordisk ha demandado a Eli Lilly en EE.UU. por presunta publicidad engañosa, alegando que Lilly compara sus tratamientos para la obesidad y diabetes con dosis antiguas de Novo Nordisk para mostrar resultados superiores. La disputa se da en la carrera por liderar el creciente mercado de fármacos contra la obesidad.
Novo Nordisk has filed a lawsuit in the US against Eli Lilly, accusing its rival of false advertising regarding the superiority of its weight-loss drugs, Mounjaro and Zepbound. Novo Nordisk claims Eli Lilly compared lower doses of Novo Nordisk's drugs with higher doses of its own, omitting newer options.
Novo Nordisk has filed a lawsuit against Eli Lilly in a U.S. court, alleging that Lilly's advertising campaigns for its obesity and diabetes drugs, Zepbound and Mounjaro, mislead consumers by using outdated clinical trials to compare efficacy against Novo's rival injections, Wegovy and Ozempic.
Eli Lilly is acquiring psychedelic drug maker AtaiBeckley for up to $3.8 billion, indicating Big Pharma's growing interest in these treatments for mental health. This follows positive clinical trial results and a Trump executive order to fast-track FDA reviews, despite past regulatory hurdles.
Ozivy, fabricado pela EMS, foi incluído na Lista de Medicamentos de Referência da Anvisa. Isso permite que outros laboratórios desenvolvam versões genéricas ou similares do medicamento no futuro, que tem o mesmo princípio ativo do Ozempic.
Medicare is launching the Bridge demonstration program to cover GLP-1 obesity drugs for eligible beneficiaries with a $50 monthly copay, a first for the program. This temporary initiative, set to expire in 2027, could unlock millions of new patients for Novo Nordisk and Eli Lilly, but raises concerns about healthcare system strain and long-term patient access.
The FDA has chosen seven companies, including Eli Lilly and Regeneron, for its PreCheck pilot program to speed up reviews of new domestic pharmaceutical manufacturing facilities. The initiative aims to cut review times by up to 14 months by allowing construction-phase inspections.
Medicare's Bridge program starts covering obesity drugs for eligible beneficiaries with a $50 monthly copay, but 82% of older Americans are unaware of this new coverage.
A RAISE US, uma nova organização bipartidária nos EUA, foi lançada com mais de US$ 500 milhões para investir em educação e capacitação profissional. Fundada por Gina Raimondo e Eric Holcomb, a iniciativa visa ajudar trabalhadores americanos a migrarem para novas carreiras em uma economia automatizada pela IA, começando por programas em quatro estados.
A single 79-year-old patient received early access to Eli Lilly's experimental obesity drug retatrutide through the FDA's compassionate use program. The unusual case has sparked speculation about the patient's identity, with questions raised if it could be former President Donald Trump.
Casos de lesão hepática foram registrados em Victoria, Austrália, após o uso de produtos com retatrutida, substância para obesidade e diabetes. Autoridades suspeitam de contaminantes em versões ilegais comercializadas online.
Stocks were mixed Tuesday as the S&P 500 dipped, with tech notably lagging. SpaceX's market cap surged past Amazon and briefly Microsoft. Eli Lilly acquired 4E Therapeutics to bolster its pain treatment pipeline. Broadcom saw insider buying amid a post-earnings sell-off.
Drugmakers are exploring new obesity treatments beyond GLP-1s, including less frequent shots and pills with fewer side effects. Eli Lilly's experimental drug retatrutide showed significant weight loss, while competitors like Novo Nordisk, Structure Therapeutics, AstraZeneca, Pfizer, and Amgen are developing new oral and injectable options. The market is expected to grow significantly, with pricing and insurance coverage being key factors.
Pharmaunternehmen Eli Lilly und Boehringer Ingelheim reduzieren geplante Investitionen in Deutschland aufgrund von Sparplänen der Bundesregierung. Ministerpräsident Schnieder versucht zu vermitteln, während die Koalition in Berlin vor einem Dilemma steht.
In April 2024, Lilly CEO David Ricks, Chancellor Olaf Scholz, Minister-President Malu Dreyer, and Health Minister Karl Lauterbach attended the groundbreaking for Lilly's new plant near Alzey, Rheinland-Pfalz. Lilly plans to invest $2.5 billion, with Lauterbach noting Germany's growing attractiveness as a pharma location.
Boehringer Ingelheim und Eli Lilly reduzieren ihre Investitionen in Deutschland aufgrund des angekündigten Spargesetzes von Gesundheitsministerin Nina Warken. Dies geschieht vor dem Hintergrund globaler Preisdruck-Diskussionen, insbesondere aus den USA.
Eli Lilly is slashing its €2.3 billion investment in a German manufacturing plant by half due to proposed healthcare cost-cutting legislation. CEO Dave Ricks criticized the reforms, warning Germany could fall behind other European markets. The reduced investment will impact factory output and job creation.
Eli Lilly and Boehringer Ingelheim are reducing planned investments in Germany, citing government austerity measures in healthcare. Eli Lilly is cutting its Alzey project by 50%, while Boehringer Ingelheim is halting €900 million in planned spending.
Boehringer Ingelheim streicht geplante Investitionen von 900 Mio. Euro in Deutschland bis 2030. Als Grund nennt das Unternehmen Sparpläne der Bundesregierung und verschlechterte Rahmenbedingungen. Eli Lilly halbiert ebenfalls Investitionen in Deutschland.
Eli Lilly reduziert seine geplanten Investitionen in eine neue Produktionsstätte in Alzey um die Hälfte und stoppt Boehringer Ingelheim geplante Ausgaben in dreistelliger Millionenhöhe. Beide Unternehmen nennen schwierige Rahmenbedingungen und Sparpläne im deutschen Gesundheitswesen als Gründe.
US-Pharmakonzern Eli Lilly reduziert geplante Milliardeninvestition in Alzey, Deutschland um 50% wegen Sparplänen der Bundesregierung. Konzernchef kritisiert Deutschland als letzten Platz bei Branchenunterstützung in Europa.
